Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	35.41B
Revenue (ttm)	7.79B
Net Income (ttm)	964.48M
Shares Out	2.60B
EPS (ttm)	0.39
PE Ratio	34.78
Forward PE	24.79
Dividend	0.18 (1.29%)
Ex-Dividend Date	Jun 18, 2025

Volume	9,101,100
Average Volume	7,284,186
Open	13.68
Previous Close	13.64
Day's Range	13.01 - 13.80
52-Week Range	6.20 - 15.08
Beta	0.99
RSI	53.15
Earnings Date	Nov 14, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY